Should the patient discontinue the Wixela (fluticasone/formoterol) inhaler and resume an albuterol inhaler for rescue, and what alternative controller medication should be prescribed to maintain asthma control?

Do Not Simply Switch Back to Albuterol Alone

The patient should NOT discontinue Wixela and return to albuterol-only therapy, as this would eliminate essential anti-inflammatory controller medication and increase the risk of severe exacerbations and asthma-related mortality. Instead, explore why the patient dislikes Wixela and transition to an alternative controller regimen that maintains asthma control while addressing their concerns 1, 2.

Understanding the Problem

Wixela Inhub (fluticasone/salmeterol) is a combination inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) used as maintenance controller therapy—not a rescue inhaler. The patient's desire to "go back to albuterol" suggests either:

• Misunderstanding of medication roles (controller vs. rescue)
• Side effects from Wixela (throat irritation, hoarseness, dry powder device issues)
• Cost concerns
• Device preference issues

Critical First Step: Identify the Specific Complaint

Ask directly:

• What specifically bothers you about Wixela? (taste, throat irritation, difficulty using the Diskus device, cost)
• Are you using albuterol separately for quick relief? (should be)
• Do you understand Wixela is daily maintenance, not rescue medication?

The Evidence Against Albuterol-Only Therapy

Current guidelines strongly recommend against using SABA (albuterol) alone without anti-inflammatory therapy 1, 2:

• Frequent SABA use (≥3 canisters/year) associates with increased mortality risk 3
• SABA monotherapy does not address underlying airway inflammation
• This approach leaves patients vulnerable to severe exacerbations

Recommended Alternative Strategies

Option 1: Switch to Anti-Inflammatory Reliever (AIR) Therapy - PREFERRED for Most Patients

For patients aged ≥12 years with mild-to-moderate asthma, prescribe budesonide-formoterol (Symbicort) as both maintenance AND rescue therapy 1, 4, 5:

• Dosing: 1-2 inhalations of budesonide-formoterol 160/4.5 mcg once or twice daily for maintenance
• Plus: Additional inhalations as needed for symptoms (up to 12 total inhalations/day)
• Advantages:
  • Single inhaler for both purposes (simplifies regimen)
  • Delivers ICS with every rescue dose (addresses inflammation when symptoms worsen)
  • Reduces severe exacerbations by 26% compared to albuterol alone 6
  • Formoterol provides rapid relief similar to albuterol

This is now the preferred Track 1 approach in GINA 2019 guidelines 1, 4.

Option 2: Budesonide-Albuterol Fixed-Dose Combination

Alternative AIR option: Prescribe budesonide-albuterol (Airsupra) 180 mcg/160 mcg as rescue therapy 6, 5:

• Use 2 inhalations as needed for symptoms
• Can be used alone in mild asthma or with separate maintenance ICS-LABA in moderate-to-severe disease
• Reduces severe exacerbations compared to albuterol alone
• Provides familiar albuterol component patients recognize

Option 3: Different ICS-LABA Controller + Separate Rescue

If the patient cannot tolerate combination therapy or prefers separate inhalers:

Maintenance options (choose based on patient preference/insurance):

• Fluticasone/vilanterol (Breo Ellipta) - once daily
• Mometasone/formoterol (Dulera) - twice daily MDI
• Budesonide/formoterol (Symbicort) - twice daily

Plus separate rescue:

• Budesonide-albuterol (Airsupra) as anti-inflammatory rescue, OR
• Albuterol MDI (if patient insists, but counsel on risks of overuse)

Option 4: Daily Low-Dose ICS for Mild Persistent Asthma

For patients aged ≥12 years with mild persistent asthma who refuse combination therapy 7:

• Daily low-dose ICS (fluticasone 88 mcg, budesonide 180 mcg, or equivalent)
• Plus albuterol for rescue
• However, this is inferior to AIR therapy for exacerbation prevention

Device-Specific Considerations

If the issue is the dry powder Diskus device (Wixela):

• Requires adequate inspiratory flow
• Can cause throat irritation, cough
• Lactose-containing (avoid if severe milk protein allergy) 8

Switch to MDI alternatives:

• Fluticasone/salmeterol MDI (AirDuo RespiClick, Wixela Inhub alternatives)
• Mometasone/formoterol MDI (Dulera)
• Budesonide/formoterol MDI (Symbicort)

Common Pitfalls to Avoid

1. Never discontinue controller therapy without replacement - this dramatically increases exacerbation risk
2. Do not prescribe albuterol alone for persistent asthma - violates current guidelines 1, 2
3. Counsel patients that using >3 SABA canisters/year signals poor control and increased mortality risk 3
4. Ensure proper inhaler technique - many "medication failures" are actually technique failures
5. Address cost barriers proactively - generic options exist for most regimens 9

Patient Education Points

Explain clearly:

• Wixela is a "preventer" taken daily, not a rescue inhaler
• Albuterol alone does not treat inflammation - the root cause of asthma
• Modern asthma care uses anti-inflammatory rescue therapy to prevent dangerous exacerbations
• Frequent albuterol use (>2 times/week) indicates poor control requiring treatment adjustment

Monitoring After Transition

• Reassess in 2-4 weeks to confirm adequate symptom control
• Track rescue inhaler use - should be <2 times/week for well-controlled asthma
• Adjust maintenance dose based on control level
• Consider step-down only after 3+ months of good control